AstraZeneca/Merck’s Lynparza Is First Adjuvant Option For BRCA-Positive Breast Cancer
Executive Summary
One of two PARP inhibitors approved in breast cancer, Lynparza may have the adjuvant breast indication all to itself for a while. One analyst projects a $1.5bn revenue opportunity for the indication.